2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2620

Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2572

Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2414

Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2385

Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2492

Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2092

Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2667

Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2118

Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2344

Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2633

Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2682

Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: L15

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2575

Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2318

Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2018

Elevated Serum Levels of Tie-1 in Patients with Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].